scholarly journals Strategies for the use of Ginkgo biloba extract, EGb 761 ® , in the treatment and management of mild cognitive impairment in Asia: Expert consensus

2020 ◽  
Author(s):  
Nagaendran Kandiah ◽  
Yee Fai Chan ◽  
Christopher Chen ◽  
Darwin Dasig ◽  
Jacqueline Dominguez ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Ginkgo Biloba ◽  
Ginkgo Biloba Extract ◽  
Expert Consensus ◽  
Egb 761

scholarly journals Effects of Ginkgo Biloba Special Extract EGb 761® in Very Mild Cognitive Impairment (vMCI)

2011 ◽  
Vol 02 (01) ◽  
pp. 48-56 ◽  
Author(s):  
Brigitte Grass-Kapanke ◽  
Arija Busmane ◽  
Andris Lasmanis ◽  
Robert Hoerr ◽  
Reiner Kaschel
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Ginkgo Biloba ◽  
Egb 761

Effectiveness and Safety Profile of Ginkgo Biloba Standardized Extract (EGb761®) in Patients with Amnestic Mild Cognitive Impairment

2021 ◽  
Vol 20 ◽  
Author(s):  
Ovidiu Băjenaru ◽  
Gabriel Prada ◽  
Florina Antochi ◽  
Cătălin Jianu ◽  
Cătălina Tudose ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Activities Of Daily Living ◽  
Ginkgo Biloba ◽  
Daily Living ◽  
Cognitive Disorders ◽  
Ginkgo Biloba Extract ◽  
Amnestic Mild Cognitive Impairment ◽  
Minimal Improvement ◽  
Severity Of Depression

Background: Ginkgo biloba is a commonsymptomatic treatment for cognitive impairment, although data on its efficacy are controversial. Objective: The aim of the current study was to evaluate the effectiveness of standardized Ginkgo biloba extract EGb761® (Tanakan®) on the improvements in cognitive functions over 24 months in a local cohort of patients diagnosed with amnestic mild cognitive impairment (aMCI). Methods: This multicentre non-interventional study included 500 eligible patients with aMCI treated with 120 mg/day standardized Ginkgo biloba extract EGb761® (Tanakan®). Patients were evaluated using several scales for assessment of cognition, memory, activities of daily living and depression (MMSE, FAQ, CGI, HAM-D) at baseline and every 6 months thereafter for a 24-month period. The median change in MMSE at the 24-month follow-up was the primary outcome of the study. Results: A statistically significant increase of 2 points in the median MMSE score was obtained. In patients with other concomitant cognitive disorders, the improvement in MMSE was less significant. Tanakan® improved memory impairment (using the delayed recall test) and the ability to accomplish activities of daily living (mean FAQ score, 1.7); it also decreased the severity of depression (mean HAM-D score, 2.4) at the end of the study. More than 80% of the patients showed at least minimal improvement of their condition as assessed by the CGI-Improvement Scale. Conclusions: The administration of EGb761® (Tanakan®) led to a significant improvement of cognitive decline, memory, activities of daily living and depression in subjects with aMCI over 24 months.

scholarly journals Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®)

2021 ◽  
Vol 14 (4) ◽  
pp. 305
Author(s):  
Carlo Tomino ◽  
Sara Ilari ◽  
Vincenzo Solfrizzi ◽  
Valentina Malafoglia ◽  
Guglielmo Zilio ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Combination Therapy ◽  
Cognitive Decline ◽  
Ginkgo Biloba ◽  
Neuropsychiatric Symptoms ◽  
The Elderly ◽  
Egb 761 ◽  
Age Related

Mild cognitive impairment (MCI) and dementia are clinically prevalent in the elderly. There is a high risk of cognitive decline in patients diagnosed with MCI or dementia. This review describes the effectiveness of Ginkgo biloba leaf special extract EGb 761® for the treatment of dementia syndromes and EGb 761® combination therapy with other medications for symptomatic dementia. This drug has shown convincing results, improving cognitive function, neuropsychiatric symptoms and consequent reduction of caregiver stress and maintenance of autonomy in patients with age-related cognitive decline, MCI and mild to moderate dementia. Currently, there is little evidence to support the combination therapy with anti-dementia drugs and, therefore, more evidence is needed to evaluate the role of EGb 761® in mixed therapy.

Sign in / Sign up

Export Citation Format

Share Document